[1] |
JIN Yiyi, ZHOU Keting, YANG Chengcheng, XU Ping, ZHU Suyan.
Osthole attenuates diabetes-induced renal injury by regulating NF-κB and p38/MAPK pathway mediated inflammatory responses
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 622-631.
|
[2] |
LIU Peng, ZHAO Hailing, SHEN Zhengri, WANG Chen, WANG Yun, QIU Xinping, LI Ping.
Tangshen formula promotes cellular cholesterol efflux in HG-induced mTECs by suppression of TGF-β1/Smad3 pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 1-9.
|
[3] |
ZHAO Shaojing, ZENG Yan, LI Zhengdong, ZHANG Hua.
Protective effects of L-carnitine on diabetic nephropathy in rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 278-282.
|
[4] |
YAO Jia, QIAO Di, GUO Xin, CUI Changmeng.
Therapeutic effects of 1-Deoxynojirimycin in mulberry leaves on rats with diabetic nephropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 517-523.
|
[5] |
JIANG Lili, MAO Limin, HU Sijia, PENG Yingzhi.
Effects of Shenshuaining granules on the expression of NF-kB and PPAR-gamma in kidney tissue of diabetic nephropathy rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 132-137.
|
[6] |
FU Yongjin, XIA Xueyi, ZHANG Xiaomu, LIU Yanbo, PAN Jingqiang, LV Junhua.
Effects of tetramethylpyrazine on the down-regulation of HMGB1 expression and reducing contents of RAGEs in diabetic nephropathy rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 846-851.
|
[7] |
YU Xiaoyi, ZHOU Zhiruo, XIE Yuan, SUN Runbin, FEI Fei, GAO Haoxue, HUANG Jingqiu, A Jiye, WANG Guangji.
Preliminary study on mechanism of tricarboxylic acid cycle disruption in diabetic nephropathy cell model
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 481-489.
|
[8] |
FAN Qiu-ling, ZHAO Xiao-ming, PU Shi, LI Sa-li, YANG Gang, JIANG Yi, WANG Li-ning.
Effects of candesartan early or late treatment on angiotensinⅡtype 1 and type 2 receptor expression in type 2 diabetic KK/Ta mice kidney
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(6): 627-633.
|
[9] |
LIU Lei, LI Liang-Zhi, HE Xian-Hong, TANG Yue-wu, SHI Ji-hong, LIU Chun-qiu, WU Ze-cheng, WANG Jun.
Cinical study of Keluoxin combined with enalapril in treatment of diabetic nephropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 211-214.
|
[10] |
HAN Su-fang.
Meta-Analysis of ACEI combined with ARB on the effect of renal function with Diabetic Nephropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(11): 1257-1262.
|
[11] |
FEI Mei-jiao.
Clinic effects of irbesartan combined with glutathione sodium on kidney in patients with diabetic nephropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(11): 1272-1275.
|
[12] |
REN Chuan-yong, XU Liang.
Observation for effect of alprostadil on uric albumin excretion of the patients with diabetic nephropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 812-814.
|
[13] |
NI Lian-song, JIN Jie-na, ZHENG Jing-chen, SHEN Fei-xia.
Effects of blocking of p38 MAPK on the signal passway of NF-κB in glomerular mesangial cells incubated with high concentration of glucose
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 13-17.
|
[14] |
SHEN Shui-juan, HU Zuo-xiang, WANG Shi-ming, LI Qing-hua.
Clinical curative effect observation of ambrette capsule combined with tripterygium glycosides tablet on diabetic nephropathy of IV stage
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 85-88.
|
[15] |
WANG Ya-min.
Progression of sulodexide and clinical application
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 109-115.
|